JP2016537982A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537982A5
JP2016537982A5 JP2016532531A JP2016532531A JP2016537982A5 JP 2016537982 A5 JP2016537982 A5 JP 2016537982A5 JP 2016532531 A JP2016532531 A JP 2016532531A JP 2016532531 A JP2016532531 A JP 2016532531A JP 2016537982 A5 JP2016537982 A5 JP 2016537982A5
Authority
JP
Japan
Prior art keywords
base pairs
nucleic acid
acid sequence
length
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537982A (ja
JP7066956B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066324 external-priority patent/WO2015077290A2/en
Publication of JP2016537982A publication Critical patent/JP2016537982A/ja
Publication of JP2016537982A5 publication Critical patent/JP2016537982A5/ja
Application granted granted Critical
Publication of JP7066956B2 publication Critical patent/JP7066956B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532531A 2013-11-19 2014-11-19 巨大遺伝子の切除および挿入 Active JP7066956B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906188P 2013-11-19 2013-11-19
US61/906,188 2013-11-19
PCT/US2014/066324 WO2015077290A2 (en) 2013-11-19 2014-11-19 Large gene excision and insertion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019230265A Division JP7036512B2 (ja) 2013-11-19 2019-12-20 巨大遺伝子の切除および挿入

Publications (3)

Publication Number Publication Date
JP2016537982A JP2016537982A (ja) 2016-12-08
JP2016537982A5 true JP2016537982A5 (enExample) 2017-12-28
JP7066956B2 JP7066956B2 (ja) 2022-05-16

Family

ID=53173682

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016532531A Active JP7066956B2 (ja) 2013-11-19 2014-11-19 巨大遺伝子の切除および挿入
JP2019230265A Active JP7036512B2 (ja) 2013-11-19 2019-12-20 巨大遺伝子の切除および挿入

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019230265A Active JP7036512B2 (ja) 2013-11-19 2019-12-20 巨大遺伝子の切除および挿入

Country Status (9)

Country Link
US (2) US10787684B2 (enExample)
EP (3) EP3604543A1 (enExample)
JP (2) JP7066956B2 (enExample)
KR (3) KR20240104191A (enExample)
AU (3) AU2014353100B2 (enExample)
CA (1) CA2930828C (enExample)
DK (1) DK3071698T3 (enExample)
ES (1) ES2754498T3 (enExample)
WO (1) WO2015077290A2 (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3540061A1 (en) 2014-04-02 2019-09-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
EP3129490A4 (en) 2014-04-08 2017-10-04 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
BR122023023211A2 (pt) 2014-04-28 2024-01-23 Recombinetics, Inc. Método de fazer edições de genes multiplex em uma célula de vertebrado ou de embrião primário não-humano
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
DK3161128T3 (en) 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
BR112017007770A2 (pt) 2014-10-15 2018-01-16 Regeneron Pharma cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3221457B1 (en) 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
DK3252162T5 (da) 2015-01-27 2024-10-07 Inst Genetics & Developmental Biology Cas Fremgangsmåde til foretagelse af stedsspecifik modifikation på hel plante via transient genekspression
CN107787367B (zh) 2015-04-06 2021-10-26 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
EP4019975A1 (en) 2015-04-24 2022-06-29 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
EP3095870A1 (en) 2015-05-19 2016-11-23 Kws Saat Se Methods for the in planta transformation of plants and manufacturing processes and products based and obtainable therefrom
WO2016196361A1 (en) 2015-05-29 2016-12-08 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
SG10201914137YA (en) 2015-06-01 2020-02-27 Univ Temple Methods and compositions for rna-guided treatment of hiv infection
AU2016280002B2 (en) 2015-06-15 2022-04-14 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
AU2016309392A1 (en) * 2015-08-14 2018-02-22 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Method for obtaining glyphosate-resistant rice by site-directed nucleotide substitution
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
AU2016349738A1 (en) * 2015-11-06 2018-05-24 The Jackson Laboratory Large genomic DNA knock-in and uses thereof
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN105861485B (zh) * 2016-04-20 2021-08-17 上海伊丽萨生物科技有限公司 一种提高基因置换效率的方法
SG10202102885UA (en) 2016-05-20 2021-05-28 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
WO2018002762A1 (en) * 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
WO2018025206A1 (en) * 2016-08-02 2018-02-08 Kyoto University Method for genome editing
US11566263B2 (en) 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
EP3500677A4 (en) * 2016-08-20 2020-04-01 Avellino Lab USA, Inc. SINGLE GUIDE RNA, CRISPR / CAS9 SYSTEMS AND METHOD FOR USE THEREOF
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
CN116732106A (zh) 2017-04-20 2023-09-12 E开创生物技术股份有限公司 产生基因修改的动物的方法
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CN111315889A (zh) * 2017-09-08 2020-06-19 生命技术公司 提高同源重组的方法和其组合物
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
WO2019093418A1 (ja) * 2017-11-13 2019-05-16 国立大学法人広島大学 哺乳動物細胞内の標的染色体部位で目的遺伝子を含むポリヌクレオチドを増幅させる方法およびベクター、ならびにその利用
US20200370070A1 (en) * 2017-11-17 2020-11-26 The Johns Hopkins University Compositions and methods for efficient genome editing
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
IL277234B2 (en) 2018-03-14 2026-03-01 Editas Medicine Inc Systems and methods for treating hemoglobin diseases
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020047531A1 (en) * 2018-08-31 2020-03-05 The Children's Hospital Of Philadelphia Scalable tagging of endogenous genes by homology-independent intron targeting
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020204159A1 (ja) * 2019-04-05 2020-10-08 国立大学法人大阪大学 ノックイン細胞の作製方法
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4085145A4 (en) * 2019-12-30 2024-02-21 The Broad Institute Inc. Guided excision-transposition systems
JP6867635B1 (ja) * 2020-04-06 2021-04-28 株式会社Logomix ゲノム改変方法及びゲノム改変キット
IL297078A (en) * 2020-04-06 2022-12-01 Logomix Inc Genome engineering method and genome engineering kit
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
JP2023520257A (ja) 2020-06-06 2023-05-16 ランザテク,インコーポレイテッド アセトラクテートデカルボキシラーゼ遺伝子座位でのノックインを有する微生物
IL302830A (en) 2020-11-13 2023-07-01 Egenesis Inc Cells, tissues, organs and animals with one or more genes that have been modified for improved survival and tolerance of a different-sex transplant
WO2022164890A2 (en) * 2021-01-26 2022-08-04 Washington State University Bacteria producing gamma-aminobutyric acid (gaba) and uses of the bacteria
WO2023039586A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
EP4426828A1 (en) 2021-11-01 2024-09-11 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
US20250057980A1 (en) 2021-12-22 2025-02-20 Tome Biosciences, Inc. Co-Delivery of a Gene Editor Construct and a Donor Template
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
CN114891750A (zh) * 2022-04-29 2022-08-12 武汉大学 筛选经cyp3a4介导代谢毒性外源化合物的细胞模型及其构建方法、应用
TWI840799B (zh) * 2022-05-02 2024-05-01 國立臺灣海洋大學 水產生物及水產品之外源性分子追溯方法及其系統
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes
WO2025224107A1 (en) 2024-04-22 2025-10-30 Basecamp Research Ltd Method and compositions for detecting off-target editing
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009009071A (es) 2007-03-02 2009-09-24 Danisco Cultivos con resistencia mejorada a fagos.
US8546553B2 (en) 2008-07-25 2013-10-01 University Of Georgia Research Foundation, Inc. Prokaryotic RNAi-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2010054108A2 (en) 2008-11-06 2010-05-14 University Of Georgia Research Foundation, Inc. Cas6 polypeptides and methods of use
WO2011053957A2 (en) 2009-11-02 2011-05-05 Gen9, Inc. Compositions and methods for the regulation of multiple genes of interest in a cell
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
CA2798703A1 (en) 2010-05-10 2011-11-17 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
EP2836226B1 (en) 2012-02-24 2017-06-28 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
ES2683071T3 (es) * 2012-04-25 2018-09-24 Regeneron Pharmaceuticals, Inc. Direccionamiento mediado por nucleasas con grandes vectores de direccionamiento
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
HK1207111A1 (en) 2012-08-03 2016-01-22 加利福尼亚大学董事会 Methods and compositions for controlling gene expression by rna processing
EP4397759A3 (en) * 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
SG10201707569YA (en) * 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
IL308158A (en) * 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US20140359795A1 (en) * 2013-05-31 2014-12-04 Recombinetics, Inc. Genetic techniques for making animals with sortable sperm
EP3603679B1 (en) * 2013-06-04 2022-08-10 President and Fellows of Harvard College Rna-guided transcriptional regulation
ES2681622T3 (es) * 2013-09-18 2018-09-14 Kymab Limited Métodos, células y organismos
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.

Similar Documents

Publication Publication Date Title
RU2016104056A (ru) Мультиплексная геномная инженерия, направляемая рнк
RU2019114706A (ru) Направляемая рнк регуляция транскрипции
WO2015200717A3 (en) Pcr-activated sorting (pas)
EA201792663A1 (ru) Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
WO2014039692A3 (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
MX388784B (es) Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
FI3690056T3 (fi) Menetelmiä ja tuotteita nukleiinihapon valmistamiseksi ja viemiseksi
WO2016025131A8 (en) Genetic targeting in non-conventional yeast using an rna-guided endonuclease
NZ705745A (en) Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
JP2017502668A5 (enExample)
IN2014DN05937A (enExample)
EA201792036A1 (ru) Способ осуществления сайт-направленной модификации растительных геномов с использованием ненаследуемых материалов
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
WO2014172470A3 (en) Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
JP2018508198A5 (enExample)
JP2016526529A5 (enExample)
EP3845640A3 (en) Modified tranposases for improved insertion sequence bias and increased dna input tolerence
WO2015108993A8 (en) Mutagenesis methods
RU2016106649A (ru) Геномная инженерия
EA201391373A1 (ru) Способы получения сложного локуса трансгенных признаков
EP4397759A3 (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
EP3972571A4 (en) METHOD USING PHOTOTHERMAL NANOPARTICLES IN RAPID NUCLEIC ACID AMPLIFICATION AND PHOTOTHERMAL NANOPARTICLES
WO2016134213A3 (en) Enhanced protein expression